Nsgene A/S
Records under this name other than patents Nsgene A/S holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,845,344 | Therapeutic use of a growth factor, NsG33 Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,334,264 | Therapeutic use of a growth factor, METRNL Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,068,015 | Therapeutic use of a growth factor, METRNL Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,675,669 | Therapeutic use of a growth factor, METRNL Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,034,918 | Therapeutic use of a growth factor, METRNL Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,121,037 | Cell Lines and Their Use in Encapsulated Cell Biodelivery Formerly held In force · High confidence | In force | High confidence | |
| US 8,404,642 | Treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,815,810 | Treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,314,502 | Treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,474,786 | Treatment of allodynia Formerly held In force · From the USPTO record | In force | From the USPTO record |